PL1913947T3 - Terapia skojarzona do leczenia raka - Google Patents

Terapia skojarzona do leczenia raka

Info

Publication number
PL1913947T3
PL1913947T3 PL07119706T PL07119706T PL1913947T3 PL 1913947 T3 PL1913947 T3 PL 1913947T3 PL 07119706 T PL07119706 T PL 07119706T PL 07119706 T PL07119706 T PL 07119706T PL 1913947 T3 PL1913947 T3 PL 1913947T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
combination therapy
effective amount
combination
Prior art date
Application number
PL07119706T
Other languages
English (en)
Inventor
Bharvin Kumar Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1913947T3 publication Critical patent/PL1913947T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07119706T 2004-04-22 2005-04-15 Terapia skojarzona do leczenia raka PL1913947T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56454004P 2004-04-22 2004-04-22
EP07119706A EP1913947B1 (en) 2004-04-22 2005-04-15 Combination therapy for the treatment of cancer
EP05738307A EP1763356B1 (en) 2004-04-22 2005-04-15 Composition comprising a survivin antisense oligonucleotide and gemcitabine for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL1913947T3 true PL1913947T3 (pl) 2012-05-31

Family

ID=35094133

Family Applications (2)

Application Number Title Priority Date Filing Date
PL05738307T PL1763356T3 (pl) 2004-04-22 2005-04-15 Kompozycja zawierająca antysensowny oligonukleotyd surwiwiny i gemcytabinę do leczenia raka
PL07119706T PL1913947T3 (pl) 2004-04-22 2005-04-15 Terapia skojarzona do leczenia raka

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL05738307T PL1763356T3 (pl) 2004-04-22 2005-04-15 Kompozycja zawierająca antysensowny oligonukleotyd surwiwiny i gemcytabinę do leczenia raka

Country Status (17)

Country Link
US (3) US20070244065A1 (pl)
EP (3) EP1763356B1 (pl)
JP (1) JP2007533742A (pl)
CN (2) CN101683355A (pl)
AT (2) ATE401088T1 (pl)
AU (1) AU2005240020B2 (pl)
BR (1) BRPI0509927A (pl)
CA (1) CA2562750A1 (pl)
CY (2) CY1110440T1 (pl)
DE (1) DE602005008241D1 (pl)
DK (2) DK1763356T3 (pl)
ES (2) ES2308488T3 (pl)
MX (1) MXPA06012132A (pl)
PL (2) PL1763356T3 (pl)
PT (2) PT1913947E (pl)
SI (2) SI1913947T1 (pl)
WO (1) WO2005107771A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2310006A4 (en) * 2008-07-03 2012-04-25 Mayo Foundation CANCER TREATMENT
FR2955112B1 (fr) 2010-01-14 2012-01-20 Isp Investments Inc Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
WO2012058462A2 (en) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
EP3154586B1 (en) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Treating lymphomas
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018045239A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
KR20230011473A (ko) 2016-09-06 2023-01-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
RU2021128415A (ru) 2016-09-06 2021-11-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
IL291917A (en) * 2019-10-02 2022-06-01 Sirnaomics Inc Oligonucleotides with nucleoside analogs, compositions comprising same and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184365B1 (en) * 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
US6077709A (en) * 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
DK1592793T3 (da) * 2003-02-10 2009-10-26 Santaris Pharma As Oligomeriske forbindelser for modulation af Survivin ekspression

Also Published As

Publication number Publication date
US20070244065A1 (en) 2007-10-18
PL1763356T3 (pl) 2008-12-31
AU2005240020B2 (en) 2011-02-10
ES2308488T3 (es) 2008-12-01
EP1763356B1 (en) 2008-07-16
EP1763356A2 (en) 2007-03-21
EP1913947A1 (en) 2008-04-23
CN101683355A (zh) 2010-03-31
DK1763356T3 (da) 2008-10-13
WO2005107771A3 (en) 2006-06-08
AU2005240020A1 (en) 2005-11-17
DK1913947T3 (da) 2012-02-06
SI1913947T1 (sl) 2012-02-29
US20090247611A1 (en) 2009-10-01
PT1913947E (pt) 2012-01-19
US20120022140A1 (en) 2012-01-26
PT1763356E (pt) 2008-09-05
ES2376484T3 (es) 2012-03-14
DE602005008241D1 (de) 2008-08-28
WO2005107771A2 (en) 2005-11-17
CN1950094A (zh) 2007-04-18
JP2007533742A (ja) 2007-11-22
EP1913947B1 (en) 2011-12-28
CA2562750A1 (en) 2005-11-17
MXPA06012132A (es) 2007-01-17
CY1110440T1 (el) 2015-04-29
SI1763356T1 (sl) 2008-12-31
BRPI0509927A (pt) 2007-09-25
ATE401088T1 (de) 2008-08-15
ATE538800T1 (de) 2012-01-15
EP2145626A1 (en) 2010-01-20
CY1112397T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
CY1112397T1 (el) Συνδυασμενη θεραπεια για την αντιμετωπιση του καρκινου
MX339142B (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
WO2004004661A3 (en) Boroproline compound combination therapy
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
GB2442915B (en) Perylenequinone derivatives and uses thereof
NO20072543L (no) Anti-cancer-behandling
WO2007130501A3 (en) Combination therapy for treatment of cancer
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
WO2005117542A3 (en) Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
EP2402435A3 (en) Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
TW200724158A (en) Combination therapy in the treatment of cancer
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
MXPA05011568A (es) Uso de irinotecan para el tratamiento de cancer recurrente de mama.
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
WO2005094803A3 (en) N3-pyridyl-thiamine and its use in cancer treatments
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture